Brief: Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
22/09/2025 12:04
Sept 22 (Reuters) - Ionis Pharmaceuticals Inc IONS.O: IONIS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL STUDY OF ZILGANERSEN IN ALEXANDER DISEASE IONIS PHARMACEUTICALS INC - PLANS NDA SUBMISSION FOR ZILGANERSEN IN Q1 2026 IONIS PHARMACEUTICALS INC - ZILGANERSEN 50 MG SHOWS SIGNIFICANT STABILIZATION IN GAIT SPEED IONIS PHARMACEUTICALS INC - ZILGANERSEN SHOWS BENEFIT IN SECONDARY ENDPOINTS IONIS PHARMACEUTICALS INC - ZILGANERSEN SHOWS FAVORABLE SAFETY AND TOLERABILITY PROFILE IONIS PHARMACEUTICALS INC: EVALUATING POTENTIAL TO INITIATE AN EXPANDED ACCESS PROGRAM (EAP) IN U.S. Source text: ID:nBwc9nZqNa Further company coverage: IONS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors